Drug intelligence / Profile preview

abemaciclib + anastrozole + pembrolizumab

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

A triplet therapy combining a CDK4/6 inhibitor (abemaciclib), an aromatase inhibitor (anastrozole), and an immune checkpoint inhibitor (pembrolizumab). This combination brings together three distinct mechanisms of action: CDK4/6 inhibition, aromatase inhibition, and immune checkpoint inhibition. It has been studied in clinical trials for hormone receptor-positive, HER2-negative metastatic breast cancer. It works by inhibiting the cell cycle, reducing estrogen production, and activating the immune system against cancer cells.

Targets

PDCD1 (Programmed cell death protein 1 receptor)CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)CYP19A1 (Aromatase)

Beyond the preview

Go deeper on abemaciclib + anastrozole + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on abemaciclib + anastrozole + pembrolizumab.

Explore the full profile